A Deeper Look into the Favorable Intermediate-Risk Patients
Deepika Bhagwat, MD, MDxHealth, presents data showing how genomic prostate score testing influences treatment decisions in favorable intermediate-risk prostate cancer. The findings highlight how GPS stratifies patients for active surveillance or definitive therapy, guiding personalized care and reducing overtreatment.
Read More